BioCentury
ARTICLE | Translation in Brief

Syntrix analgesic overcomes tramadol’s dependence on CYP2D6

Syntrix is creating desmetramadol as a safer and less variable version of tramadol

June 13, 2019 9:19 PM UTC

Bypassing the metabolic conversion required for Schedule IV opiate tramadol to achieve analgesia, Syntrix has positioned desmetramadol as a safer and more effective pain therapy.

Tramadol has been positioned as less likely to cause lethal respiratory depression than other opioids, and to carry less potential for abuse. But because it is metabolized by cytochrome P450 2D6 (CYP2D6), both its potency and safety vary among patients depending on their CYP2D6 status...

BCIQ Company Profiles

Syntrix Pharmaceuticals

BCIQ Target Profiles

Cytochrome P450 2D6 (CYP2D6)